Michael E. Nassif

Sep 4, 2024 | jamanetwork.com | Ahmad Masri |Michael E. Nassif |Kansas City |Roberto Barriales-Villa

Key PointsQuestion  Does aficamten treatment improve exercise response beyond peak oxygen uptake (pVO2) measured by cardiopulmonary exercise testing in obstructive hypertrophic cardiomyopathy (HCM)? Findings  In the Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Obstructive HCM (SEQUOIA-HCM) randomized clinical trial, 282 patients with symptomatic obstructive HCM received aficamten or placebo for 24 weeks.

Aug 1, 2023 | jacc.org | Suzanne Arnold |Daniel Silverman |Kensey L. Gosch |Michael E. Nassif

1. "2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction". J Am Coll Cardiol . 2021;77:6: 772-810. https://doi.org/10.1016/j.jacc.2020.11.022. 2.